A court partially dismissed Eli Lilly's lawsuit against Empower Pharmacy, a Houston compounding pharmacy that makes GLP-1 drugs (weight-loss and diabetes medications). The case involves a dispute over whether pharmacies can legally make cheaper copies of these drugs.

• •Court partially dismissed Eli Lilly's lawsuit against Empower Pharmacy
• •Empower is a Houston compounding pharmacy producing GLP-1 drugs
• •Case centers on legality of compounded copies of GLP-1 medications

A judge threw out part of Eli Lilly's lawsuit against Empower Pharmacy, a Houston company that makes GLP-1 drugs (weight-loss and diabetes medicines) without a brand name. The decision limits how much of Eli Lilly's case can move forward in court.

• •Judge dismissed part of Eli Lilly's GLP-1 lawsuit against Empower Pharmacy
• •Empower is a Houston-based compounder of GLP-1 drugs
• •Ruling limits scope of Lilly's case going forward

Counterfeit tirzepatide (a weight-loss and diabetes drug) was discovered in India's Haryana region, prompting Eli Lilly to warn people to buy the drug only with a prescription from a doctor. The company is trying to stop fake versions from reaching patients.

• •Counterfeit tirzepatide discovered in Haryana, India
• •Eli Lilly issued a safety warning urging prescription-only purchases
• •Company taking action to prevent fake versions reaching patients

Early research has found a possible link between Wegovy (a semaglutide weight-loss drug) and a rare eye condition sometimes called an 'eye stroke.' The finding is based on early data and doctors are still studying whether the drug itself causes this problem or if other factors are involved.

• •Early research links Wegovy to a rare eye condition called 'eye stroke'
• •Causality between semaglutide and the condition is not yet established

A company posted fake customer testimonials while claiming to sell GLP-1 weight-loss drugs, but had no actual pharmacy license. The FDA issued a warning about the fraudulent operation.

• •FDA issued a warning over a fraudulent GLP-1 weight-loss seller
• •Operator posted fake customer testimonials
• •Company had no actual pharmacy license

A medical case study describes a patient who developed high blood calcium levels while taking tirzepatide (a weight-loss and diabetes drug) and calcium supplements together. The report suggests doctors should watch for this rare combination effect in patients on tirzepatide.

• •Case report describes hypercalcemia in a patient on tirzepatide plus calcium supplementation
• •Authors recommend clinician vigilance for this drug-supplement interaction
• •Published as a Cureus case report